Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Glycogen storage disease type II (Pompe disease) causes death in infancy from cardiorespiratory failure due to acid alpha-glucosidase (GAA; acid maltase) deficiency. An AAV2 vector pseudotyped as AAV6 (AAV2/6 vector) transiently expressed high-level human GAA in GAA-knockout (GAA-KO) mice without reducing glycogen storage; however, in immunodeficient GAA-KO/SCID mice the AAV2/6 vector expressed high-level GAA and reduced the glycogen content of the injected muscle for 24 weeks. A CD4+/CD8+ lymphocytic infiltrate was observed in response to the AAV2/6 vector in immunocompetent GAA-KO mice. When a muscle-specific creatine kinase promoter was substituted for the CB promoter (AAV-MCKhGAApA), that AAV2/6 vector expressed high-level GAA and reduced glycogen content in immunocompetent GAA-KO mice. Muscle-restricted expression of hGAA provoked only a humoral (not cellular) immune response. Intravenous administration of a high number of particles of AAV-MCKhGAApA as AAV2/7 reduced the glycogen content of the heart and skeletal muscle and corrected individual myofibers in immunocompetent GAA-KO mice 24 weeks postinjection. In summary, persistent correction of muscle glycogen content was achieved with an AAV vector containing a muscle-specific promoter in GAA-KO mice, and this approach should be considered for muscle-targeted gene therapy in Pompe disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 5×
“The lack of transgene expression in the diaphragm with an AAV vector containing the MCK promoter/enhancer was previously reported [13] and could be related to lower activity of that promoter in transduced diaphragm.”
BackgroundInfluentialGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“AAV2/1 and AAV2/7 vectors demonstrated increased transduction of muscle fibers compared to AAV2/2 vectors [9–11].”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 1×
“The mechanism for induction of tolerance to liver-targeted expression of FIX involved regulatory CD4 T cells that suppressed neutralizing antibody formation, and higher levels of FIX expression increased the likelihood of tolerance [25].”
BackgroundMount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L. (2001) · Human Gene Therapy · doi:10.1089/104303401750061267 · Cited by 152
Fields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127
Research works printed but not linked: 39
- Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc. Natl. Acad. Sci. USA, 96, 8861, 10.1073/pnas.96.16.8861 · DOI · Paper page
- Pauly, 2001, Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease, Hum. Gene Ther., 12, 527, 10.1089/104303401300042447 · DOI
- Ding, 2001, Long-term efficacy after [E1−, polymerase−] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice, Hum. Gene Ther., 12, 955, 10.1089/104303401750195917 · DOI · Paper page
- Raben, 2003, Enzyme replacement therapy in the mouse model of Pompe disease, Mol. Genet. Metab., 80, 159, 10.1016/j.ymgme.2003.08.022 · DOI · Paper page
- Pauly, 1998, Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle, Gene Ther., 5, 473, 10.1038/sj.gt.3300609 · doi:10.1038/sj.gt.3300609
- Fraites, 2002, Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors, Mol. Ther., 5, 571, 10.1006/mthe.2002.0580 · DOI · Paper page
- Sun, 2003, Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector, Mol. Ther., 7, 467, 10.1016/S1525-0016(03)00022-4 · DOI
- Sun, 2003, Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector, Mol. Ther., 7, 193, 10.1016/S1525-0016(02)00055-2 · DOI
- Rabinowitz, 2002, Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol., 76, 791, 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Rutledge, 1998, Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 1, J. Virol., 72, 309, 10.1128/JVI.72.1.309-319.1998 · DOI · Paper page
- Ferrer, 2000, Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy, Gene Ther., 7, 1439, 10.1038/sj.gt.3301259 · DOI
- Hauser, 2000, Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors, Mol. Ther., 2, 16, 10.1006/mthe.2000.0089 · DOI · Paper page
- Shield, 1996, E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice, Mol. Cell. Biol., 16, 5058, 10.1128/MCB.16.9.5058 · DOI · Paper page
- Yuasa, 2002, Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product, Gene Ther., 9, 1576, 10.1038/sj.gt.3301829 · DOI
- Ding, 2002, Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction, Mol. Ther., 5, 436, 10.1006/mthe.2002.0563 · DOI
- Raben, 2001, Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy, Hum. Mol. Genet., 10, 2039, 10.1093/hmg/10.19.2039 · DOI
- Fraites, 2002, Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors, Mol. Ther., 5, 571, 10.1006/mthe.2002.0580 · DOI · Paper page
- Wang, 1999, Sustained correction of bleeding disorder in hemophilia B mice by gene therapy, Proc. Natl. Acad. Sci. USA, 96, 3906, 10.1073/pnas.96.7.3906 · DOI · Paper page
- Monahan, 1998, Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia, Gene Ther., 5, 40, 10.1038/sj.gt.3300548 · DOI · Paper page
- Herzog, 2002, Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy, Hum. Gene Ther., 13, 1281, 10.1089/104303402760128513 · DOI · Paper page
- Zolotukhin, 2002, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther., 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
- Halbert, 2001, Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors, J. Virol., 75, 6615, 10.1128/JVI.75.14.6615-6624.2001 · DOI · Paper page
- O’Riordan, 2000, Scalable chromatographic purification process for recombinant adeno-associated virus (rAAV), J. Gene Med., 2, 444, 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1 · DOI
- Kaludov, 2002, Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography, Hum. Gene Ther., 13, 1235, 10.1089/104303402320139014 · DOI · Paper page
- Gao, 2000, Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo, Hum. Gene Ther., 11, 2079, 10.1089/104303400750001390 · DOI · Paper page
- Liu, 2003, Optimized production of high-titer recombinant adeno-associated virus in roller bottles, Biotechniques, 34, 184, 10.2144/03341dd07 · DOI · Paper page
- Zhang, 1999, High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H, Hum. Gene Ther., 10, 2527, 10.1089/10430349950016861 · DOI · Paper page
- Urabe, 2002, Insect cells as a factory to produce adeno-associated virus type 2 vectors, Hum. Gene Ther., 13, 1935, 10.1089/10430340260355347 · DOI · Paper page
- Amalfitano, 1997, Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy, Gene Ther., 4, 258, 10.1038/sj.gt.3300378 · DOI
- He, 1998, A simplified system for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. USA, 95, 2509, 10.1073/pnas.95.5.2509 · DOI · Paper page
- Fang, 2003, Development of a new, immune-deficient, GSD-II mouse model confirms that anti-GAA antibody can limit the efficacy of gene therapy for GSD-II, Mol. Ther., 7, S390, 10.1016/S1525-0016(16)41454-1 · doi:10.1016/s1525-0016(16)41454-1
- Raben, 1998, Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II, J. Biol. Chem., 273, 19086, 10.1074/jbc.273.30.19086 · DOI · Paper page
- Fujimori, 1997, The murine DNA-PKcs gene consists of 86 exons dispersed in more then 250 kb, Genomics, 45, 194, 10.1006/geno.1997.4919 · DOI
- Blunt, 1996, Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse, Proc. Natl. Acad. Sci. USA, 93, 10285, 10.1073/pnas.93.19.10285 · DOI · Paper page
- Araki, 1997, Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice, Proc. Natl. Acad. Sci. USA, 94, 2438, 10.1073/pnas.94.6.2438 · DOI · Paper page
- Kikuchi, 1998, Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail, J. Clin. Invest., 101, 827, 10.1172/JCI1722 · DOI · Paper page
- Van Hove, 1996, High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proc. Natl. Acad. Sci. USA, 93, 65, 10.1073/pnas.93.1.65 · DOI
- Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc. Natl. Acad. Sci. USA, 96, 8861, 10.1073/pnas.96.16.8861 · DOI · Paper page
Cited by
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Pompe disease diagnosis and management guideline
Kishnani, P. S., Steiner, R. D., Bali, D., Berger, K., Byrne, B. J., Case, L. E., Crowley, J. F., Downs, S., Howell, R. R., Kravitz, R. M., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000218152.87434.f3 · Cited by 632
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Recent studies demonstrate that it is possible to achieve correction in skeletal muscle (Franco et al. 2005; Sun et al. 2005a).”
BackgroundInfluential
Metadata
- Authors
- Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 11
- Issue
- 6
- Pages
- 889-898
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2034661134
- Cited by
- 111
- References
- 8
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4146 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.